1.A tumor mimic: Rare presentation of pituitary adenoma as central diabetes insipidus with subsequent bright spot recovery – A case report.
Philippine Journal of Internal Medicine 2026;64(1):100-104
BACKGROUND
Central diabetes insipidus (CDI) is a common complication following transsphenoidal surgery for pituitary adenomas, but CDI as an initial presentation in pituitary adenomas is extremely rare. We report a case of a 67-year-old Filipino male with pituitary macroadenoma presenting as central diabetes insipidus, manifesting as a two-month history of severe frontotemporal headache, increased thirst, and polyuria, which was managed with desmopressin followed by transsphenoidal surgery. Three months postoperatively, the thyroid and adrenocorticotropic axis remained intact, and pituitary bright spot recovery was observed. He was clinically stable; hence, desmopressin was gradually tapered and discontinued. This case report presents a unique case of a pituitary adenoma that initially presented with central DI but later showed a complete resolution of symptoms along with the normalization of the "bright spot" seen on MRI, a hallmark of the posterior pituitary. Treatment options for preoperative CDI may include surgical or medical management, with some cases reported as self-limiting. However, the rarity of such cases underscores the urgent need for more clinical studies to fully understand the course of this condition. This case highlights a unique presentation of central diabetes insipidus in a pituitary macroadenoma and the possibility of complete resolution of symptoms coinciding with pituitary bright spot recovery post operatively.
Adenoma ; Diabetes Insipidus ; Diabetes Insipidus, Neurogenic ; Neoplasms ; Pituitary Neoplasms ; Research Report
2.Malignant Hypernatremia Complicating a Hypothalamic Tumor: An Endocrine Emergency
Vijayrama Rao Sambamoorthy ; Man Ee Chiew ; Xe Hui Lee
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):94-
Introduction:
Hypernatremia is a common yet high-mortality electrolyte
disorder. The hypothalamus maintains water homeostasis
via thirst sensation and arginine vasopressin (AVP)
secretion. Hypothalamic tumors, such as gliomas, can progressively destroy these osmoregulatory centres, leading to
“malignant” hypernatremia (>180 mmol/L). We report a
case of life-threatening hypernatremia in a patient with a
progressive hypothalamic glioma, exploring its complex
pathophysiology.
Case:
A 41-year-old female with a progressive high-grade
hypothalamic glioma and persistent hydrocephalus
presented with generalized weakness, reduced oral intake,
and dehydration. Her initial Glasgow Coma Scale was
E4V3M6. Laboratory investigations revealed malignant
hypernatremia (serum sodium 209 mmol/L) and a serum
osmolarity of 441 mOsm/kg. Despite life-threatening
dehydration (urea 26.2 mmol/L, creatinine 343 umol/L),
she was still able to deceptively produce urine output of
400 mL/day with a concentrated urine osmolarity of 890
mOsm/kg. A 1 mcg IV desmopressin trial reduced urine
output to 60 mL/day and serum sodium by 10 mmol/L
within 14 hours, confirming relative AVP deficiency.
The patient’s malignant hypernatremia was gradually
corrected to 168 mmol/L over 1 week (8–12 mmol/L/day)
using controlled intravenous hydration. However, her
condition deteriorated due to hospital-acquired infection,
and she succumbed 10 days after admission.
Conclusion
This case underscores several critical learning points for
managing hypothalamic emergencies. First, hypothalamic
tumors can reset the osmostat or destroy osmoregulatory
centres, causing adipsic AVP deficiency. Second, clinicians
must be alert to “masked polyuria” where severe hypovolemia reduces the glomerular filtration rate, causing
urine output to appear “normal” despite underlying AVP
deficiency. This state of “relative polyuria” is a hallmark
of hypothalamic hypernatremia, thus indicating that a
normal urine output does not rule out AVP deficiency.
While desmopressin is indicated, its use in adipsic patients
demands strict fluid titration to prevent iatrogenic hyponatremia. Rapid hypotonic correction carries a proven risk of cerebral oedema, and sodium measurement accuracy varies
significantly across laboratory methods in extreme ranges.
Hypernatremia
;
Hypothalamic Neoplasms
3.Coexistence of Nonfunctioning Pituitary Adenoma and Graves’ Disease: A Diagnostic Challenge
Alexander Kam ; Dinda Aprilia ; Eva Decroli ; Syafril Syahbuddin ; Yanne Pradwi Efendi ; Athari Fadhila Namanda Putri
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):98-
Introduction:
Nonfunctioning pituitary adenomas (NFPA) may cause
central hypothyroidism due to pituitary compression, often
presenting with low thyroid-stimulating hormone (TSH).
However, suppressed TSH in this setting should not automatically be attributed to pituitary dysfunction, as primary
hyperthyroidism—such as Graves’ disease—may rarely
coexist. Distinguishing between these disorders is essential
to avoid misdiagnosis and inappropriate management.
Case:
A 42-year-old female presented with intermittent headache, visual field impairment, palpitations, fine tremors,
and weight loss. Physical examination revealed visual field
deficits and no goiter.
Laboratory evaluation showed cortisol level of 1 µg/dL
(normal: 3.7–19.4 µg/dL), luteinizing hormone 1.62 mU/L
(normal: 2.4–12.6 mU/L), follicle-stimulating hormone 5.01
mU/L (normal: 3.5–12.5 mU/L), free thyroxine 4 28.32 pmol/L
(normal: 12–22 pmol/L), TSH 0.02 µIU/mL (normal: 0.27–4.2
µIU/mL), and prolactin 70.84 ng/mL. Thyrotropin receptor
antibody (TRAb) was 3.53 IU/L, confirming Graves’ disease.
Contrast-enhanced brain magnetic resonance imaging
demonstrated a pituitary macroadenoma (2.13 × 2.28 × 3.05
cm) with optic chiasm compression. The patient was diagnosed with NFPA, Graves’ disease,
secondary adrenal insufficiency, possible hypogonadotropic
hypogonadism, and hyperprolactinemia likely due to the
stalk effect.
Preoperative management included hydrocortisone replacement and antithyroid therapy. The patient subsequently
underwent transsphenoidal surgery with appropriate
perioperative care. Postoperatively, no new pituitary
hormone deficiencies were observed. She was maintained
on thiamazole 10 mg daily with clinical improvement and
remains under regular follow-up.
Conclusion
This case highlights a rare but clinically important coexistence of NFPA and Graves’ disease. Suppressed TSH in
patients with pituitary adenoma should not be assumed to
reflect pituitary dysfunction without thorough evaluation.
Comprehensive thyroid assessment is crucial to ensure
accurate diagnosis and appropriate management.
Pituitary Neoplasms
;
Graves Disease
4.A Diagnostic Masquerade: Resistance to Thyroid Hormone Mimicking TSH-Secretory Pituitary Adenoma
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):119-
Introduction:
Discordant thyroid function tests (TFTs), characterized
by elevated free thyroxine 4 (FT4) with non-suppressed
thyroid-stimulating hormone (TSH), pose a significant
diagnostic challenge. Differentiating between Resistance
to Thyroid Hormone (RTH) and TSH-secreting pituitary
adenoma (TSH-oma) is essential, as management strategies
differ substantially.
Case:
A female with a history of hyperthyroidism diagnosed in
2011 was treated with antithyroid drugs for 1 year before
defaulting on follow-up. She was later found to have
discordant TFTs at a private centre, where a brain computed tomography scan was reportedly normal. She was referred
to our centre for optimization of thyroid function prior
to planned thyroidectomy for a solitary large right
thyroid nodule measuring 4.2 × 2.8 × 4.7 cm. Fine-needle
aspiration cytology demonstrated a benign follicular lesion
(Bethesda II).
Despite restarting antithyroid medication, she remained
clinically euthyroid with no overt thyrotoxic symptoms
apart from intermittent palpitations without documented
tachycardia. Antithyroid therapy was discontinued.
Serial TFTs across multiple assay platforms consistently
demonstrated elevated FT4 with inappropriately normal
TSH levels. Thyroid autoantibodies, including TSH receptor
and anti-thyroid peroxidase antibodies, were negative.
Pituitary magnetic resonance imaging showed no evidence
of adenoma, and serum α-subunit level was normal (0.3 ng/
mL), making TSH-oma unlikely. Dynamic testing was not
performed as thyrotropin-releasing hormone stimulation
was unavailable at our centre, while T3 suppression testing
was deemed inappropriate due to symptomatic palpitations. Family screening was not possible as the patient
was not in contact with her relatives. In the absence of
pituitary pathology and given her largely euthyroid clinical
status, RTH was considered the most likely diagnosis.
Conclusion
This case highlights the importance of considering RTH
in patients with persistent discordant TFTs, particularly
when clinical findings do not correlate with biochemical
abnormalities. Early recognition and appropriate pituitary
evaluation are essential to prevent misdiagnosis and avoid
unnecessary antithyroid therapy or thyroidectomy.
Pituitary Neoplasms
;
Thyroid Hormones
;
Thyrotropin
5.Molecular Plot Twist: H3 G34V Mutation and MET Amplification in a Diffuse Hemispheric Glioma
Viktoria Madelaine R. Beltran ; Edwin L. Muñ ; oz ; Marie Christine F. Bernardo
Philippine Journal of Pathology 2026;(75th PSP Research Competition Abstracts):1-
Introduction:
Diffuse hemispheric glioma, H3G34-mutant (DHG-H3G34m) (CNS
WHO grade 4), is a rare, recently characterized subtype of pediatric high-grade glioma.
This is the first histopathologically and molecularly confirmed case of DHG-H3G34m
in the Philippines, underscoring the rarity of the tumor and the growing capacity for
molecular neuropathologic diagnostics in the country
Case Description:
This is a case of a 16-year-old male with a right fronto-parietal
tumor. MRI and CT scan shows a large, lobulated, contrast-enhancing mass. Histologic
examination reveals a hypercellular neoplasm with sheets of pleomorphic cells with
hyperchromatic nuclei, irregular nuclear membranes, and moderate amphophilic
cytoplasm. Foci of multinucleated giant cells, microcalcifications, microvascular
proliferation, and necrosis are seen. Immunohistochemical studies (IHCs) with GFAP
and H3 G34V reveal diffuse positivity. There is loss of expression of OLIG2 and ATRX.
Molecular analysis revealed alterations in H3-3A G34V, TP53, ATRX, and an ST7::MET
fusion leading to MET amplification.
Discussion:
The working diagnosis prior to IHCs was High Grade Neoplasm with
differentials of epithelioid glioblastoma, glioblastoma with giant cell features and
anaplastic ependymoma. The IHC and molecular findings support the diagnosis of
DHG-H3G34m. DHG-H3G34m are caused by mutations in the H3-3A gene which alter
the 34th amino acid in the H3.3 histone. Usually a glycine-to-arginine (G34R) mutation
is found, but in few instances such as in this case, there is a glycine-to-valine (G34V)
mutation. These have poor prognosis with no known targetable treatment; however,
the MET fusion found in this case may possibly be treated with MET-tyrosine kinase
inhibitors.
Conclusion
This is a case of diffuse hemispheric glioma, H3G34-mutant (CNS WHO
grade 4) with a rare H3 G34V mutation and MET amplification in a 16-year-old male,
the first histomorphologically and molecularly confirmed case in the Philippines.
Child
;
Brain Neoplasms
;
Glioma
6.Presenting characteristics, histological subtypes and outcomes of adult central nervous system tumours: retrospective review of a surgical cohort.
Mervyn Jun Rui LIM ; Yilong ZHENG ; Sean Wai-Onn ENG ; Celest Wen Ting SEAH ; Shuning FU ; Lucas Zheng Long LAM ; Joel Yat Seng WONG ; Balamurugan VELLAYAPPAN ; Andrea Li-Ann WONG ; Kejia TEO ; Vincent Diong Weng NGA ; Sein LWIN ; Tseng Tsai YEO
Singapore medical journal 2025;66(10):545-550
INTRODUCTION:
The most recent local study on the incidence of histological subtypes of all brain and spinal tumours treated surgically was published in 2000. In view of the outdated data, we investigated the presenting characteristics, histological subtypes and outcomes of adult patients who underwent surgery for brain or spinal tumours at our institution.
METHODS:
A single-centre retrospective review of 501 patients who underwent surgery for brain or spinal tumours from 2016 to 2020 was conducted. The inclusion criteria were (a) patients who had a brain or spinal tumour that was histologically verified and (b) patients who were aged 18 years and above at the time of surgery.
RESULTS:
Four hundred and thirty-five patients (86.8%) had brain tumours and 66 patients (13.2%) had spinal tumours. Patients with brain tumours frequently presented with cranial nerve palsy, headache and weakness, while patients with spinal tumours frequently presented with weakness, numbness and back pain. Overall, the most common histological types of brain and spinal tumours were metastases, meningiomas and tumours of the sellar region. The most common complications after surgery were cerebrospinal fluid leak, diabetes insipidus and urinary tract infection. In addition, 15.2% of the brain tumours and 13.6% of the spinal tumours recurred, while 25.7% of patients with brain tumours and 18.2% of patients with spinal tumours died. High-grade gliomas and metastases had the poorest survival and highest recurrence rates.
CONCLUSION
This study serves as a comprehensive update of the epidemiology of brain and spinal tumours and could help guide further studies on brain and spinal tumours.
Humans
;
Retrospective Studies
;
Female
;
Male
;
Middle Aged
;
Adult
;
Aged
;
Central Nervous System Neoplasms/pathology*
;
Brain Neoplasms/pathology*
;
Treatment Outcome
;
Postoperative Complications
;
Young Adult
;
Spinal Neoplasms/pathology*
;
Neoplasm Recurrence, Local
;
Aged, 80 and over
;
Adolescent
7.Research progress on platelets in glioma.
Mingrong ZUO ; Tengfei LI ; Zhihao WANG ; Yufan XIANG ; Siliang CHEN ; Yanhui LIU
Chinese Medical Journal 2025;138(1):28-37
Gliomas are the most common primary neuroepithelial tumors of the central nervous system in adults, of which glioblastoma is the deadliest subtype. Apart from the intrinsically indestructible characteristics of glioma (stem) cells, accumulating evidence suggests that the tumor microenvironment also plays a vital role in the refractoriness of glioblastoma. The primary functions of platelets are to stop bleeding and regulate thrombosis under physiological conditions. Furthermore, platelets are also active elements that participate in a variety of processes of tumor development, including tumor growth, invasion, and chemoresistance. Glioma cells recruit and activate resting platelets to become tumor-educated platelets (TEPs), which in turn can promote the proliferation, invasion, stemness, and chemoresistance of glioma cells. TEPs can be used to obtain genetic information about gliomas, which is helpful for early diagnosis and monitoring of therapeutic effects. Platelet membranes are intriguing biomimetic materials for developing efficacious drug carriers to enhance antiglioma activity. Herein, we review the recent research referring to the contribution of platelets to the malignant characteristics of gliomas and focusing on the molecular mechanisms mediating the interaction between TEPs and glioma (stem) cells, as well as present the challenges and opportunities in targeting platelets for glioma therapy.
Humans
;
Glioma/metabolism*
;
Blood Platelets/physiology*
;
Brain Neoplasms/pathology*
;
Tumor Microenvironment
8.Unlocking therapeutic potential: Exploring nuclear receptors in brain cancer treatment.
Sujitha JAYAPRAKASH ; Hiu Yan LAM ; Ravichandran VISHWA ; Bandari BHARATHWAJCHETTY ; Kenneth C-H YAP ; Mohammed S ALQAHTANI ; Mohamed ABBAS ; Gautam SETHI ; Alan Prem KUMAR ; Ajaikumar B KUNNUMAKKARA
Chinese Medical Journal 2025;138(21):2722-2752
Brain cancer remains among the most lethal malignancies worldwide, with approximately 321,476 new cases and 248,305 deaths reported globally in 2022. The treatment of malignant brain tumors presents substantial clinical challenges, primarily due to their resistance to standard therapeutic approaches. Despite decades of intensive research, effective treatment strategies for brain cancer are still lacking. Nuclear receptors (NRs), a superfamily of ligand-activated transcription factors, regulate a broad range of physiological processes including metabolism, immunity, stress response, reproduction, and cellular differentiation. Increasing evidence highlights the involvement of NRs in oncogenesis, with several members demonstrating altered expression and function in brain tumors. Aberrations in NR signaling, encompassing receptors such as androgen receptors, estrogen receptors, estrogen-related receptors, glucocorticoid receptors, NR subfamily 4 group A, NR subfamily 1 group D member 2, NR subfamily 5 group A member 2, NR subfamily 2 group C member 2, liver X receptors, peroxisome-proliferator activated receptors, progesterone receptors, retinoic acid receptors, NR subfamily 2 group E member 1, thyroid hormone receptors, vitamin D receptors, and retinoid X receptors, have been implicated in promoting hallmark malignant phenotypes, including enhanced survival, proliferation, invasion, migration, metastasis, and resistance to therapy. This review aims to explore the roles of key NRs in brain cancer, with an emphasis on their prognostic significance, and to evaluate the therapeutic potential of targeting these receptors using selective agonists or antagonists.
Humans
;
Brain Neoplasms/drug therapy*
;
Receptors, Cytoplasmic and Nuclear/metabolism*
;
Animals
;
Signal Transduction/physiology*
10.Ophthalmologic findings of parachiasmal lesions in a tertiary Philippine hospital
Kevin John D. Sy ; Franz Marie O. Cruz
Acta Medica Philippina 2025;59(7):67-73
BACKGROUND AND OBJECTIVE
A parachiasmal lesion is defined as a mass or growth arising from structures around or near the chiasm. Ophthalmologic signs and symptoms may be observed in such condition, such as blurring of vision, visual field defects, and binocular double vision. The primary objective of this study was to describe the presenting ophthalmologic signs and symptoms of parachiasmal lesions among patients consulting at a single institution in the Philippines.
METHODSThis was a single-center, retrospective, cohort study. Medical records of patients with parachiasmal lesions seen in the Neuro-Ophthalmology clinic of a tertiary Philippine hospital from January 2014 to December 2019 were reviewed. Clinical profile, neuro-ophthalmologic presentation, diagnosis, management, and visual outcomes were summarized by descriptive statistics.
RESULTSOne hundred thirty-three (133) patient records satisfied the study criteria. Most common presenting symptoms were blurring of vision. headache, and loss of vision. Visual acuity at initial visit ranged from 20/20 to no light perception. A relative afferent pupillary defect was present in half of the study population. Almost half presented with normal-looking discs or disc pallor. Bitemporal hemianopia is the most common visual field defect pattern seen in both confrontation and automated visual field testing. Histopathology was significantly associated with visual outcome.
CONCLUSIONParachiasmal lesion should be suspected in patients who complain of unilateral blurring of vision, and those who present with normal or pale optic discs. Pituitary adenoma is the most common radiologic and histopathologic diagnosis. Visual outcome after intervention has improved or remained stable in two-thirds of patients; visual recovery is multi-factorial, which is influenced by duration, surgery, and histopathology.
Human ; Retrospective Studies ; Pituitary Neoplasms ; Visual Fields ; Visual Acuity ; Philippines


Result Analysis
Print
Save
E-mail